Ultrasound-Assisted Thrombolysis for Heart Attack
(SONOSTEMILYSIS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will assess the safety and feasibility of sonothrombolysis in the acute management of STEMI undergoing reperfusion therapy with systemic fibrinolysis as part of a pharmacoinvasive approach
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking medications that are contraindicated with the study's treatments, such as certain anticoagulants or aspirin, you may need to adjust your medication regimen.
How does ultrasound-assisted thrombolysis differ from other heart attack treatments?
Ultrasound-assisted thrombolysis for heart attacks is unique because it combines ultrasound waves with a contrast agent, like Definity, to enhance the breakdown of blood clots. This method can accelerate clot dissolution and improve blood flow more quickly compared to traditional clot-busting drugs alone.12345
What data supports the effectiveness of the treatment Definity® for heart attacks?
The research primarily discusses the use of Definity® as an ultrasound contrast agent to improve heart imaging, which helps in better diagnosing heart conditions. While it doesn't directly address heart attack treatment, its ability to enhance cardiac imaging could indirectly support better management of heart-related issues.12356
Are You a Good Fit for This Trial?
This trial is for heart attack patients over 30 years old who are receiving clot-dissolving therapy within 6 hours of symptom onset. It's specifically for those with high-risk ECG patterns indicating severe heart attacks. People can't join if they're allergic to ultrasound contrast agents, have a bleeding disorder, major heart shunts, took experimental treatments recently, had prior bypass surgery or are in cardiogenic shock.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sonothrombolysis or standard therapy for STEMI within 6 hours of symptom onset
Follow-up
Participants are monitored for safety and effectiveness after treatment, including serial echocardiography assessments
Long-term follow-up
Patient outcomes are followed for 1 year after reperfusion
What Are the Treatments Tested in This Trial?
Interventions
- Definity®
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alberta
Lead Sponsor
Canadian VIGOUR Centre
Collaborator